BlossomHill Therapeutics (NASDAQ:BLSM) Raised to Strong-Buy at Guggenheim

BlossomHill Therapeutics (NASDAQ:BLSM) was upgraded by stock analysts at Guggenheim to a “strong-buy” rating in a report issued on Tuesday, Zacks reports.

A number of other equities analysts have also recently issued reports on BLSM. Wall Street Zen upgraded shares of BlossomHill Therapeutics to a “hold” rating in a research report on Saturday, August 15th. Lifesci Capital assumed coverage on shares of BlossomHill Therapeutics in a research report on Tuesday. They issued an “outperform” rating and a $32.00 price target on the stock. HC Wainwright began coverage on BlossomHill Therapeutics in a research report on Tuesday. They set a “buy” rating and a $35.00 price objective for the company. JPMorgan Chase & Co. assumed coverage on BlossomHill Therapeutics in a research note on Tuesday. They issued an “overweight” rating and a $28.00 target price on the stock. Finally, Leerink Partners assumed coverage on BlossomHill Therapeutics in a report on Tuesday. They set an “outperform” rating and a $36.00 target price on the stock. Three analysts have rated the stock with a Strong Buy rating and two have given a Buy rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Strong Buy” and a consensus target price of $32.20.

BlossomHill Therapeutics Price Performance

Shares of BLSM stock opened at $18.99 on Tuesday. BlossomHill Therapeutics has a fifty-two week low of $15.25 and a fifty-two week high of $20.61.

Insider Buying and Selling at BlossomHill Therapeutics

In other news, Director Carl L. Gordon bought 625,000 shares of the firm’s stock in a transaction that occurred on Monday, August 10th. The shares were purchased at an average price of $16.00 per share, for a total transaction of $10,000,000.00. Following the completion of the transaction, the director owned 2,714,279 shares in the company, valued at $43,428,464. The trade was a 29.91% increase in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director John P. Schmid purchased 6,000 shares of the business’s stock in a transaction on Monday, August 10th. The stock was acquired at an average price of $16.00 per share, with a total value of $96,000.00. Following the completion of the acquisition, the director directly owned 6,000 shares in the company, valued at $96,000. The trade was a ∞ increase in their position. The SEC filing for this purchase provides additional information. In the last ninety days, insiders have bought 1,573,900 shares of company stock valued at $25,181,900.

About BlossomHill Therapeutics

BlossomHill Therapeutics Inc is a clinical-stage biopharmaceutical company applying an intentional, chemistry-based approach to design and develop small molecule medicines which address significant unmet medical needs in cancer treatment. The company’s lead clinical programs include BH-30643. BlossomHill Therapeutics Inc is headquartered in San Diego, California.